Inventiva Gelecekteki Büyüme
Future kriter kontrolleri 3/6
Inventiva kazanç ve gelirin sırasıyla yıllık 56.1% ve 51.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 40.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 33.8% olacağı tahmin edilmektedir.
Anahtar bilgiler
56.1%
Kazanç büyüme oranı
40.08%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 59.9% |
| Gelir büyüme oranı | 51.3% |
| Gelecekteki özkaynak getirisi | 33.81% |
| Analist kapsamı | Good |
| Son güncelleme | 10 Jul 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Anlatı Güncellemesi • Jun 17
IVA: Equity Raise And New Financing Will Support Upcoming MASH Milestones
Analysts have adjusted their price target on Inventiva to €15.37 from €11.40, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E, along with recent Street research such as Stifel's revised target. What's in the News for Inventiva Inventiva completed a follow on equity offering of American Depositary Shares, raising about US$120.0 million through the issuance of 27,272,727 ADSs at a price of US$4.40 per security, at a discount of US$0.264 per ADS.
Anlatı Güncellemesi • Jun 03
IVA: 2026 MASH Phase 3 Milestones Will Drive Bullish Repricing Potential
Analysts have nudged their fair value estimate for Inventiva slightly higher to about €10.09, reflecting updated assumptions on the discount rate and future P/E following a lower price target from Stifel and a fresh bullish initiation from Truist. Analyst Commentary Recent research views on Inventiva point in different directions, with bullish analysts focusing on long term upside potential and bearish analysts placing more weight on execution risks and valuation discipline.Anlatı Güncellemesi • May 19
IVA: 2026 MASH Phase 3 Readout Will Underpin Bullish Repricing Outlook
Analysts have trimmed their fair value estimate for Inventiva slightly from about €10.00 to about €9.97, pointing to updated assumptions around profit margins and a higher future P/E that balance recent caution from one research house with a more bullish initiation from another. Analyst Commentary Bullish Takeaways Bullish analysts see the slightly higher assumed future P/E as support for the idea that investors may be willing to pay up for the stock if execution on the current pipeline stays on track.Anlatı Güncellemesi • May 04
IVA: 2026 MASH Phase 3 Readout Will Drive Repricing Thesis
Analysts have trimmed their price target on Inventiva by €2, reflecting slightly more cautious revenue growth assumptions, expectations for stronger profit margins, and a marginally lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see the revised price target as still consistent with meaningful upside potential if Inventiva can deliver on revenue expectations and margin improvement.Anlatı Güncellemesi • Apr 20
IVA: 2026 MASH Phase 3 Readout Will Support Repricing Thesis
Analysts now see Inventiva’s fair value holding at €10.00, with the latest price target update explained by a slightly higher discount rate, adjusted revenue growth and margin assumptions, and a lower future P/E multiple following recent initiation and target revision reports from several firms. Analyst Commentary Recent Street research on Inventiva points to a mix of optimism around the long term setup and caution around execution risk.Anlatı Güncellemesi • Apr 06
IVA: 2026 MASH Phase 3 Readout Will Drive Repricing Narrative
The analyst price target for Inventiva has shifted from €8.98 to about €10.00, reflecting updated analyst views that balance a slightly higher discount rate with Street research highlighting lanifibranor's profile in MASH and recent supportive coverage from multiple firms. Analyst Commentary Street research around Inventiva centers on how effectively the company can turn lanifibranor's MASH profile into a de-risked late stage asset and how that potential squares with recent price target resets and rating changes.Anlatı Güncellemesi • Mar 23
IVA: Bullish MASH Program Coverage Will Highlight Upcoming Clinical Milestone Catalysts
The analyst price target for Inventiva has been revised to €11.40. This reflects analysts' use of a slightly higher discount rate, an updated view on very large revenue growth potential, and adjusted future P/E assumptions informed by recent bullish initiations and upgrades on the stock.Anlatı Güncellemesi • Mar 08
IVA: 2026 MASH Phase 3 Readout Expected To Drive Bullish Repricing
Analysts have increased their average price target for Inventiva to €12, up from €3, citing fresh bullish initiations and upgrades that highlight lanifibranor's differentiated profile in metabolic dysfunction-associated steatohepatitis, its inclusion among preferred small and mid cap biotech names with key upcoming catalysts, and its broader pipeline. Analyst Commentary Recent research coverage clusters around a constructive view on Inventiva, with several firms setting price targets around €12 and highlighting both the lead MASH asset and the broader pipeline as key pieces of the story.Anlatı Güncellemesi • Feb 21
IVA: 2026 MASH Phase 3 Readout Will Support Bullish Repricing View
Analysts have raised their Inventiva fair value estimate from €7.85 to approximately €8.98, citing recent Buy and Outperform initiations that underscore confidence in lanifibranor's MASH potential and a modest increase in the assumed future P/E multiple. Analyst Commentary Recent research coverage paints a generally constructive picture for Inventiva, with several firms starting or updating views that focus on lanifibranor's potential in MASH and re-rating the shares using higher P/E assumptions and price targets.Anlatı Güncellemesi • Feb 07
IVA: Bullish Coverage And Equity Raises Will Highlight Upcoming MASH Catalyst
The analyst price target for Inventiva has moved from $10.00 to $11.40 as analysts factor in recent bullish initiations and upgrades that highlight lanifibranor's profile in MASH and identify the company as part of a group with key upcoming catalysts and broader pipelines. Analyst Commentary Bullish analysts are clustering around a constructive view on Inventiva, pointing to recent initiations and upgrades that anchor higher valuation frameworks to the MASH opportunity and the broader pipeline.Anlatı Güncellemesi • Jan 22
IVA: 2026 Phase 3 MASH Readout Will Drive Bullish Repricing Narrative
Narrative Update on Inventiva Analysts have raised their price targets on Inventiva to a range of about US$12 to US$13 per share, up from around US$3 in earlier research. They cite new Outperform and Buy ratings that highlight lanifibranor's pan PPAR profile in MASH and upcoming clinical catalysts as key supports for a higher valuation framework.Anlatı Güncellemesi • Jan 08
IVA: 2026 Phase 3 MASH Readout Expected To Unlock Upside Repricing
Analysts have raised their price target on Inventiva to $12 from $3, citing growing confidence in upcoming lanifibranor data, a broader biotech re-rating, and what they view as a de-risked, best-in-class pipeline with multiple catalysts ahead. Analyst Commentary Recent Street research around Inventiva clusters around a more constructive view of its lead asset lanifibranor and the company’s late stage pipeline, which analysts link directly to their higher valuation frameworks and upgraded views on the stock.Anlatı Güncellemesi • Dec 23
IVA: 2026 Phase 3 MASH Data Will Drive Upside Repricing
Analysts have modestly reduced their price target on Inventiva to $7.85 from $8.20 while maintaining a constructive stance based on expectations that lanifibranor could show superior fibrosis improvement in the pivotal Phase 3 NATiV3 trial, which is expected in the second half of 2026. Analyst Commentary Bullish analysts highlight that despite the modest reduction in the price target, the longer term valuation framework remains driven by the potential of lanifibranor to outperform currently approved MASH therapies on fibrosis endpoints.Anlatı Güncellemesi • Dec 09
IVA: 2026 Phase 3 Fibrosis Data Will Drive Significant Upside Potential
Analysts have modestly raised their price target on Inventiva to $13.00, reflecting increased confidence in lanifibranor's potential for superior fibrosis improvement ahead of the pivotal Phase 3 NATiV3 data, which is expected in the second half of 2026. Analyst Commentary Recent Street research highlights a generally constructive stance on Inventiva, anchored by optimism around lanifibranor's potential differentiation in the emerging MASH treatment landscape and the value inflection expected around the Phase 3 NATiV3 readout in the second half of 2026.Analiz Makalesi • Dec 03
These Analysts Think Inventiva S.A.'s (EPA:IVA) Sales Are Under Threat
The latest analyst coverage could presage a bad day for Inventiva S.A. ( EPA:IVA ), with the analysts making...Anlatı Güncellemesi • Nov 25
IVA: Upcoming 2026 Phase 3 Data Will Unlock Significant Upside Potential
Inventiva's analyst price target has been raised from $7.95 to $8.20 per share. This increase reflects growing optimism among analysts due to increased confidence in lanifibranor's potential Phase 3 efficacy and expanding market opportunities.Anlatı Güncellemesi • Nov 06
IVA: Phase 3 Readout Will Drive Future Upside Amid Bullish Coverage
Analysts have maintained their fair value estimate for Inventiva at $7.95, citing continued optimism around forthcoming Phase 3 data. There is also a growing consensus on the promising outlook for lanifibranor in the MASH market.Analiz Makalesi • Oct 31
The Price Is Right For Inventiva S.A. (EPA:IVA) Even After Diving 30%
Inventiva S.A. ( EPA:IVA ) shares have retraced a considerable 30% in the last month, reversing a fair amount of their...Anlatı Güncellemesi • Oct 23
Analysts Boost Inventiva Price Target Amid Optimism for MASH Market and Pipeline Progress
Analysts have raised their average price target for Inventiva from $9 to $13 per share, citing increased optimism for the Metabolic-Associated Steatohepatitis market as well as a larger anticipated target patient population. Analyst Commentary Bullish Takeaways Bullish analysts have increased their price targets, reflecting heightened enthusiasm for the Metabolic-Associated Steatohepatitis market and an anticipated expansion in the eligible patient population.Anlatı Güncellemesi • Oct 09
Phase III Trials Will Advance Lanifibranor For MASH Treatment
Analysts have increased their fair value estimate for Inventiva from $6.45 to $7.95 per share. They cited greater conviction in revenue growth potential and profit margins for its lead asset in the metabolic disease market.Analiz Makalesi • Oct 08
Revenue Downgrade: Here's What Analysts Forecast For Inventiva S.A. (EPA:IVA)
The latest analyst coverage could presage a bad day for Inventiva S.A. ( EPA:IVA ), with the analysts making...Analiz Makalesi • Sep 04
Need To Know: The Consensus Just Cut Its Inventiva S.A. (EPA:IVA) Estimates For 2025
Today is shaping up negative for Inventiva S.A. ( EPA:IVA ) shareholders, with the analysts delivering a substantial...Analiz Makalesi • Aug 15
There's Reason For Concern Over Inventiva S.A.'s (EPA:IVA) Massive 27% Price Jump
The Inventiva S.A. ( EPA:IVA ) share price has done very well over the last month, posting an excellent gain of 27...
Yeni Anlatı • Apr 02
Phase III Trials Will Advance Lanifibranor For MASH Treatment
Strategic focus on lanifibranor development, cutting other activities, and reducing workforce may improve net margins through operational efficiency.Analiz Makalesi • Apr 02
Need To Know: Analysts Are Much More Bullish On Inventiva S.A. (EPA:IVA)
Inventiva S.A. ( EPA:IVA ) shareholders will have a reason to smile today, with the analysts making substantial...Analiz Makalesi • Feb 27
Revenues Not Telling The Story For Inventiva S.A. (EPA:IVA) After Shares Rise 36%
Inventiva S.A. ( EPA:IVA ) shares have had a really impressive month, gaining 36% after a shaky period beforehand. But...Analiz Makalesi • Sep 27
Inventiva S.A. (EPA:IVA) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
Unfortunately for some shareholders, the Inventiva S.A. ( EPA:IVA ) share price has dived 28% in the last thirty days...Analiz Makalesi • Jun 18
More Unpleasant Surprises Could Be In Store For Inventiva S.A.'s (EPA:IVA) Shares After Tumbling 28%
Inventiva S.A. ( EPA:IVA ) shareholders that were waiting for something to happen have been dealt a blow with a 28...Analiz Makalesi • Jun 14
Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why
Key Insights Inventiva to hold its Annual General Meeting on 20th of June Total pay for CEO Frederic Cren includes...Analiz Makalesi • Mar 19
Optimistic Investors Push Inventiva S.A. (EPA:IVA) Shares Up 27% But Growth Is Lacking
Those holding Inventiva S.A. ( EPA:IVA ) shares would be relieved that the share price has rebounded 27% in the last...Analiz Makalesi • Jan 16
Some Confidence Is Lacking In Inventiva S.A.'s (EPA:IVA) P/S
When close to half the companies in the Biotechs industry in France have price-to-sales ratios (or "P/S") below 5.8x...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 214 | -51 | 80 | 34 | 10 |
| 12/31/2027 | 118 | -86 | 341 | 200 | 11 |
| 12/31/2026 | 5 | -146 | -47 | -74 | 11 |
| 12/31/2025 | 7 | -354 | -105 | -105 | N/A |
| 9/30/2025 | 12 | -333 | -98 | -98 | N/A |
| 6/30/2025 | 17 | -311 | -91 | -91 | N/A |
| 3/31/2025 | 16 | -248 | -89 | -89 | N/A |
| 12/31/2024 | 14 | -184 | -86 | -86 | N/A |
| 9/30/2024 | 17 | -144 | -86 | -85 | N/A |
| 6/30/2024 | 19 | -104 | -85 | -85 | N/A |
| 3/31/2024 | 21 | -107 | -84 | -83 | N/A |
| 12/31/2023 | 23 | -110 | -82 | -82 | N/A |
| 9/30/2023 | 22 | -95 | -73 | -73 | N/A |
| 6/30/2023 | 22 | -80 | -64 | -64 | N/A |
| 3/31/2023 | 20 | -67 | -55 | -54 | N/A |
| 12/31/2022 | 18 | -54 | -45 | -45 | N/A |
| 9/30/2022 | 14 | -55 | -50 | -49 | N/A |
| 6/30/2022 | 10 | -56 | -55 | -54 | N/A |
| 3/31/2022 | 10 | -56 | -54 | -53 | N/A |
| 12/31/2021 | 9 | -50 | -48 | -48 | N/A |
| 9/30/2021 | 7 | -45 | -46 | -45 | N/A |
| 6/30/2021 | 6 | -41 | -44 | -43 | N/A |
| 3/31/2021 | 5 | -36 | -35 | -35 | N/A |
| 12/31/2020 | 5 | -34 | -31 | -31 | N/A |
| 9/30/2020 | 7 | -29 | -24 | -24 | N/A |
| 6/30/2020 | 10 | -25 | -17 | -17 | N/A |
| 3/31/2020 | 10 | -27 | -23 | -23 | N/A |
| 12/31/2019 | 11 | -30 | -29 | -28 | N/A |
| 9/30/2019 | 9 | -34 | N/A | -33 | N/A |
| 6/30/2019 | 7 | -37 | N/A | -38 | N/A |
| 3/31/2019 | 8 | -35 | N/A | -35 | N/A |
| 12/31/2018 | 7 | -33 | N/A | -34 | N/A |
| 9/30/2018 | 8 | -29 | N/A | -27 | N/A |
| 6/30/2018 | 9 | -25 | N/A | -21 | N/A |
| 3/31/2018 | 9 | -22 | N/A | -19 | N/A |
| 12/31/2017 | 10 | -19 | N/A | -17 | N/A |
| 9/30/2017 | 11 | -16 | N/A | -18 | N/A |
| 6/30/2017 | 13 | -13 | N/A | -19 | N/A |
| 3/31/2017 | 14 | -10 | N/A | -17 | N/A |
| 12/31/2016 | 14 | -7 | N/A | -15 | N/A |
| 9/30/2016 | 13 | -8 | N/A | -14 | N/A |
| 6/30/2016 | 12 | -8 | N/A | -13 | N/A |
| 3/31/2016 | 10 | -9 | N/A | -13 | N/A |
| 12/31/2015 | 9 | -9 | N/A | -14 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: IVA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Kazançlar ve Piyasa: IVA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Yüksek Büyüme Kazançları: IVA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Gelir ve Pazar: IVA şirketinin gelirinin (yıllık 51.3% ) French pazarından (yıllık 5.8% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: IVA şirketinin gelirinin (yıllık 51.3% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: IVA 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 33.8 %)
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/13 11:40 |
| Gün Sonu Hisse Fiyatı | 2026/07/13 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Inventiva S.A. 23 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Eliana Merle | Barclays |
| Edward Nash | Canaccord Genuity |
| Etzer Darout | Guggenheim Securities, LLC |